---
marp: true
theme: default
paginate: true
footer: "PHA 548 â€¢ Melatonin/Orexin/Buspirone/Barbiturates â€¢ MedChem"
style: |
  section {
    font-family: Helvetica, sans-serif;
    font-size: 20px;
    text-align: left;
    padding: 40px;
  }
  h1 { font-size: 40px; }
  h2 { font-size: 30px; margin-bottom: 15px; }
---

# â­ Lecture 03  
## Alternative Hypnotic Pathways  
Melatonin Agonists â€¢ DORAs â€¢ Buspirone â€¢ Barbiturates

---

## ðŸŽ¯ Learning Objectives

Students will be able to:

1ï¸âƒ£ Recognize pharmacophores of melatonin agonists *(Understand)*  
2ï¸âƒ£ Evaluate orexin antagonist structure vs half-life *(Analyze/Evaluate)*  
3ï¸âƒ£ Distinguish buspirone from sedative-hypnotics *(Understand/Apply)*  
4ï¸âƒ£ Explain barbiturate SAR impacting potency & duration *(Analyze)*  

---

## ðŸŒ‘ Melatonin Agonists

### MT1/MT2 GPCR Target
- Circadian control in SCN  
- Endogenous melatonin too short-acting

---

## Ramelteon â€” Design Strategy

**Structure**
- **Non-indole bicyclic** core  
- Amide chain mimics natural ligand  
- MT2 affinity > MT1 â†’ reinforces sleep onset

**PK**
- CYP1A2 major metabolism  
- Active metabolite M-II extends duration slightly  

**Clinical Notes**
- No withdrawal / dependence â†’ **not controlled**

---

## Tasimelteon â€” Circadian Drug

- Similar melatonin-mimetic topology  
- Improves **sleep-wake rhythm entrainment**  
- Approved for **Non-24** (blind or sighted)

---

## ðŸ¦´ Orexin Receptor Antagonists (DORAs)

### Why?
Block **wake drive** â†’ allow natural sleep architecture

**Shared MedChem Traits**
- Large, aromatic **hydrophobic cores**
- Amide / urea H-bonding

---

## Suvorexant, Lemborexant, Daridorexant

| Drug | Duration Strategy | Notes |
|------|------------------|------|
| Suvorexant | Lipophilic â†’ long-acting | Next-day effects risk |
| Lemborexant | Moderately long | Less amnesia |
| Daridorexant | Shorter tÂ½ via clearance tuning | Favorable safety |

**Mechanistic Pearl**
- **No** GABA\_A action  
â†’ Less cognitive/respiratory suppression

---

## Buspirone â€” Not a Hypnotic

**Target:** Partial agonist **5-HT1A**  

**Structure**
- **Azaspirodecanedione** scaffold  
- Bulky â†’ slow CNS penetration

**Clinical**
- **Anxiety relief** without sedation  
- Zero hypnotic effect  
- Weeks for onset â€” *not useful for insomnia*

---

## ðŸ”¥ Barbiturates â€” Foundational SAR

Base: **barbituric acid**  
Activity requires: **5,5-disubstituted**

**SAR Rules**
| Modification | Effect |
|-------------|--------|
| â†‘ C-chain length/branching | â†‘ lipophilicity, potency |
| S-for-O at C2 (thiobarbiturates) | â†‘ lipophilicity â†’ rapid onset |
| Add polar OH | Shorter duration via renal clearance |

---

## Mechanistic Contrast

| Feature | Barbiturates | BZDs/Z-drugs |
|--------|--------------|--------------|
| Requires GABA? | âŒ (direct channel opening at high doses) | âœ” |
| AMPA blockade | âœ” | âŒ |
| Lethality risk | HIGH | Low-moderate |

â†’ **Reason for clinical displacement** except anesthesia + seizures.

---

## Active Learning (Team-Based)

> Which would you choose for insomnia in a patient with:
>  
> ðŸš« BZD misuse history  
>  
> A) Eszopiclone  
> B) Diazepam  
> C) **Ramelteon** ðŸ‘‰ Best  
> D) Thiopental  

*(Bloom: Evaluate clinical implications of SAR)*

---

## Summary

- **Melatonin agonists:** Circadian alignment  
- **DORAs:** Block wakefulness via orexin  

- **Buspirone:** Anxiety only â€” **never hypnosis**  
- **Barbiturates:** Strong CNS depressants, **high risk**

---

## Assessment Mapping

| Target | Item style |
|--------|------------|
| SAR | Structure modification MCQs |
| PK | Case-based |
| Mechanistic comparison | Concept-based MCQs |

---

# Questions?
